Novavax may be years away from a potential approval of its RSV vaccine, but on the company's recent year-end conference call, executives talked up the candidate's commercial appeal and the steps they're taking now to prepare for a possible rollout.
SUBSCRIBE
Biohealth Innovation
Founding Member of
